Cite

HARVARD Citation

    Kawamura, T. et al. (2018). Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data. Cancer science. 109 (9), pp. 2822-2829. [Online]. 
  
Back to record